Debt SecuritiesIndenture • February 4th, 2021 • Ocuphire Pharma, Inc. • Pharmaceutical preparations • New York
THIS INDENTURE, dated as of [●], 20___, between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
AS WARRANT AGENTPreferred Stock Warrant Agreement • February 4th, 2021 • Ocuphire Pharma, Inc. • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
OCUPHIRE PHARMA, INC. AND __________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF _____________Common Stock Warrant Agreement • February 4th, 2021 • Ocuphire Pharma, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
OCUPHIRE PHARMA, INC. AND ___________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF _________Warrant Agreement • February 4th, 2021 • Ocuphire Pharma, Inc. • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
